drugset / Trial / NCT00308607
Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether combination therapy with bevacizumab (Avastin), dacarbazine and interferon-alfa-2a (Roferon-A) is effective in patients with locally advancing or metastatic melanoma.
Timeline
- Start
- 2005-08
- Primary completion
- 2008-12
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | Dacarbazine | Small molecule | — | — |
| Background | interferon alfa | Protein / enzyme biologic | — | Subcutaneous |